. 2021 Apr 19;36(2):279–295. doi: 10.3803/EnM.2021.964

Table 3.

Changes in LDL-C in Studies with Inclisiran in Patients with Familial Hypercholesterolemia

Study, duration, and reference	Patients, number and type	Treatment	Change in LDL-C, %
ORION-2, 180 days, Hovingh et al. (2020) [89]	4 HoFH	I 300 mg on days 1 and 90/104	−37.0 to 3.3

ORION-5, 24 months, (NCT03851705) [90]	56 HoFH randomized 2:1 to I or placebo	Placebo on days 1, 90	Awaited
ORION-5, 24 months, (NCT03851705) [90]	56 HoFH randomized 2:1 to I or placebo	I 300 mg on days 1, 90, 270, 450, 630	Awaited

ORION-9, 18 months, Raal et al. (2020) [73]	240 HeFH	Placebo on days 1, 90, 270, 450	8.2 (4.3 to 12.2)
ORION-9, 18 months, Raal et al. (2020) [73]	242 HeFH	I 300 mg on days 1, 90, 270, 450	−39.7 (−43.7 to −35.7)

Values are expressed as range or mean (95% confidence interval).

LDL-C, low-density lipoprotein cholesterol; HoFH, homozygous familial hypercholesterolemia; I, inclisiran; HeFH, heterozygous familial hypercholesterolemia.